Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masayuki Isaji

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Kidney International. Supplement|March 2, 2011
SGLT2 inhibitors: molecular design and potential differences in effectMasayuki Isaji
Current Opinion in Investigational Drugs (London, England : 2000)|April 27, 2007
Sodium-glucose cotransporter inhibitors for diabetesMasayuki Isaji
Journal of Structural Biology|December 30, 2008
Crystal structures of the apo and holo form of rat catechol-O-methyltransferaseEiichi Tsuji, Kosuke Okazaki, Masayuki Isaji, et al.
European Journal of Pharmacology|July 21, 2009
Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) miceKenji Katsuno, Yoshikazu Fujimori, Yukiko Ishikawa-Takemura, et al.
ACS Medicinal Chemistry Letters|March 28, 2015
Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitorsKazuya Tatani, Masahiro Hiratochi, Yoshinori Nonaka, et al.
European Journal of Pharmacology|January 22, 2005
Rat model of the hypercalcaemia induced by parathyroid hormone-related protein: characteristics of three bisphosphonatesYoshimitsu Komatsu, Yohsuke Imai, Fumiaki Itoh, et al.
European Journal of Pharmacology|June 28, 2005
Adiponectin receptor 2 expression in liver and insulin resistance in db/db mice given a beta3-adrenoceptor agonistFumiki Oana, Hiroo Takeda, Akane Matsuzawa, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 28, 2008
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent modelsYoshikazu Fujimori, Kenji Katsuno, Ikumi Nakashima, et al.
Metabolism: Clinical and Experimental|August 11, 2005
Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectinFumiki Oana, Hiroo Takeda, Kohichi Hayakawa, et al.
Pharmacological Research|July 20, 2005
DNA microarray analysis of white adipose tissue from obese (fa/fa) Zucker rats treated with a beta3-adrenoceptor agonist, KTO-7924Fumiki Oana, Toshiki Homma, Hiroo Takeda, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Kidney International. Supplement|March 2, 2011
SGLT2 inhibitors: molecular design and potential differences in effectMasayuki Isaji
Current Opinion in Investigational Drugs (London, England : 2000)|April 27, 2007
Sodium-glucose cotransporter inhibitors for diabetesMasayuki Isaji
Journal of Structural Biology|December 30, 2008
Crystal structures of the apo and holo form of rat catechol-O-methyltransferaseEiichi Tsuji, Kosuke Okazaki, Masayuki Isaji, et al.
European Journal of Pharmacology|July 21, 2009
Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) miceKenji Katsuno, Yoshikazu Fujimori, Yukiko Ishikawa-Takemura, et al.
ACS Medicinal Chemistry Letters|March 28, 2015
Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitorsKazuya Tatani, Masahiro Hiratochi, Yoshinori Nonaka, et al.
European Journal of Pharmacology|January 22, 2005
Rat model of the hypercalcaemia induced by parathyroid hormone-related protein: characteristics of three bisphosphonatesYoshimitsu Komatsu, Yohsuke Imai, Fumiaki Itoh, et al.
European Journal of Pharmacology|June 28, 2005
Adiponectin receptor 2 expression in liver and insulin resistance in db/db mice given a beta3-adrenoceptor agonistFumiki Oana, Hiroo Takeda, Akane Matsuzawa, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 28, 2008
Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent modelsYoshikazu Fujimori, Kenji Katsuno, Ikumi Nakashima, et al.
Metabolism: Clinical and Experimental|August 11, 2005
Physiological difference between obese (fa/fa) Zucker rats and lean Zucker rats concerning adiponectinFumiki Oana, Hiroo Takeda, Kohichi Hayakawa, et al.
Pharmacological Research|July 20, 2005
DNA microarray analysis of white adipose tissue from obese (fa/fa) Zucker rats treated with a beta3-adrenoceptor agonist, KTO-7924Fumiki Oana, Toshiki Homma, Hiroo Takeda, et al.
Pageof 3